A hypothesis for the pathogenesis of myelodysplastic syndromes: Implications for new therapies

Leukemia

Volumn 14, Issue 1, 2000, Pages 2-8

  Rosenfeld, C ^a   List, A ^b  

^a TEXAS ONCOLOGY   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Acute nonlymphocytic leukemia; Myelodysplastic syndrome; Preleukemia; Refractory anemia

Indexed keywords

FAS LIGAND; TUMOR NECROSIS FACTOR ALPHA;

APLASTIC ANEMIA; BONE MARROW CELL; CANCER INHIBITION; CELL CLONE; CELL PROLIFERATION; CELL SURVIVAL; DISEASE COURSE; HEMATOPOIETIC STEM CELL; HUMAN; MUTATION; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TELOMERE;

EID: 0033967640     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401618     Document Type: Review

References (113)

1. Greenberg PL, Nichols WC, Schrier SL. Granulopoiesis in acute myeloid leukemia and preleukemia. New Engl J Med 1971; 22: 1225-1232.
2. Rosati S, Anastasi J, Vardiman J. Recurring diagnostic problems in the pathology of the myelodysplastic syndromes. Semin Hematol 1996; 33: 111-126.
3. Asano H, Ohashi H, Ichihara M, Kinoshita T, Murate T, Kobayashi M, Saito H, Hotta T. Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes. Blood 1994; 84: 588-594.
4. Delforge M, Demuynck H, Vandenberghe P, Verhoef G, Zachée P, Van Duppen V, Marijnen P, Van den Berghe H, Boogaerts M. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood 1995; 86: 3660-3667.
5. Delforge M, Demuynck H, Verhoef G, Vandenberghe P, Zachée P, Maertens J, Duppen VV, Boogaerts MA. Patients with high risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission. Br J Haematol 1998; 102: 486-494.
6. List AF, Jacobs A. Pathogenesis and biology of myelodysplasia. Semin Oncol 1992; 29: 14-24.
7. Sanz GF, Sanz MA, Vallespi T. Etiopathogeny, prognosis and therapy of myelodysplastic syndromes. Hematol Cell Ther 1997; 39: 277-294.
8. Gallagher A, Darley RL, Padua R. The molecular basis of myelodysplastic syndromes. Haematologica 1997; 82: 191-204.
9. Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 1998; 83: 71-86.
10. West RR, Stafford DA, Farrow A, Jacobs A. Occupational and environmental exposures and myelodysplasia: a case-control study. Leukemia Res 1995; 19: 127-139.
11. Nisse C, Grandbastien B, Brizard A, Hebbar M, Haguenoer JM, Fenaux P. Myelodysplastic syndromes (MDS) and exposure to occupational or environmental hazards: a case-control study. Blood 1997; 90 (Suppl. 1): 518a (Abstr.).
12. Rigolin GM, Cuneo A, Roberti MG, Bardi A, Bigoni R, Piva N, Minotto C, Agostini P, Angeli CD, Senno LD. Exposure to myelotoxic agents and myelodysplasia: case-control study and correlation with clinobiologic findings. Br J Haematol 1998; 103: 189-197.
13. 609C->T polymorphism in the NAD(P)H: quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999; 94: 803-807.
14. Takaku S, Takaku F. Natural killer cell activity and preleukaemia. Lancet 1981; 2: 1178.
15. List AF, Glinsmann-Gibson B, Spier C, Taetle R. In vitro and in vivo response to cyclosporin-A in myelodysplastic syndromes (MDS): identification of a hypocellular subset responsive to immune suppression. Blood 1992; 80 (Suppl. 1): 28a (Abstr.).
16. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Hematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vβ profiles. Br J Haematol 1998; 102: 1314-1322.
17. Van Kamp H, Fibbe WE, Jansen RPM, van der Keur M, de Graaff E, Willemze R, Landegent JE. Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene. Blood 1992; 80: 1774-1780.
18. Hamblin TJ. Imnumological abnormalities in myelodysplastic syndromes. Semin Hematol 1996; 33: 150-162.
19. Tefferi A, Thibodeau SN, Solberg LA. Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. Blood 1990; 75: 1770-1773.
20. Kibbelaar RE, van Kamp H, Dreef EJ, de Groot-Swings G, Kluin-Nelemans JC, Beverstock GC, Fibbe WE, Kluin M. Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes. Blood 1992; 79: 1823-1828.
21. Anastasi J, Feng J, Le Beau M, Larson RA, Rowley JD, Vardiman JW. Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion. Blood 1993; 81: 1580-1585.
22. Kroef MJPL, Fibbe WE, Mout R, Jansen RPM, Haak HL, Wessels JW, Van Kamp H, Willemze R, Landegent JE. Myeloid but not lymphoid cells carry the 5 q deletion: polymerase chain reaction analysis of loss of heterozygosity using mini-repeat sequences on highly purified cell fractions. Blood 1993; 81: 1849-1854.
23. Sulecki M, Shadduck RK, Zeigler Z. Anti-thymocyte globulin for hypoplastic myelodysplastic syndrome. Blood 1988; 72 (Suppl. 1): 229a (Abstr.).
24. Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy tor hypoplastic myelodysplastic syndrome. Cancer 1997; 79: 1548-1551.
25. Molldrem J, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99: 699-705.
26. Jonás̄ová A, Neuwirtová R, C̄ermák J, Vozobulová V, Mociková K, Šis̄ková M, Hochová I. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998; 100: 304-309.
27. Rosenfeld CS, Zeigler ZR, Shadduck RK, Nilsson B. Phase II study of roquinimex in myelodysplastic syndrome. Am J Clin Oncol 1997; 20: 189-192.
28. Nand S, Stock W, Stiff P, Sosman J, Martone B, Radvany R. A phase II trial of interleukin-2 in myelodysplastic syndromes. Br J Haematol 1998; 101: 205-207.
29. Saitoh K, Miura I, Takahashi N, Miura AB. Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes. Blood 1998; 92: 2886-2892.
30. Selleri C, Sato T, Anderson S, Young NS, Maciejewski JP. Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol 1995; 165: 538-546.
31. Nagafuji K, Shibuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T, Okamura T, Gondo H, Niho Y. Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood 1995; 86: 883-889.
32. Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD344+ human marrow cells is induced by interteron γ and tumor necrosis factor α and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995; 85: 3183-3190.
33. Zoumbos N, Symeonidis A, Kourakli A, Katevas P, Matsouka P, Perraki M, Georgoulias V. Increased levels of soluble interleukin-2 receptors and tumor necrosis factor in serum of patients with myelodysplastic syndromes. Blood 1991; 77: 413-414.
34. Verhoef GEG, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 1992; 12: 1268-1272.
35. Stasi R, Brunetti M, Bussa S, Conforti M, Martin LS, Presa ML, Bianchi M, Parma A, Pagano A. Serum levels of tumour necrosis factor-α predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome. Clin Lab Haematol 1997; 19: 197-201.
36. Koike M, Ishiyama T, Tomoyasu S, Tsuruoka N. Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndromes and aplastic anemia. Leukemia Res 1995; 19: 639-644.
37. Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahaski M, Tanizawa T, Kamiyama R, Hirokawa K. Overexpression of tumor necrosis factor (TNF)-α and Interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997; 11: 2049-2054.
38. Kitagawa M, Kamiyama R, Kasuga T. Increase in number of bone marrow macrophages in patients with myelodysplastic syndromes, Eur J Haematol 1993; 51: 56-58.
39. Shetty V, Mundle S, Alvi S, Showel M, Broady-Robinson L, Dar S, Borok R, Showel J, Gregory S, Rifkin S, Gezer S, Parcharidou A, Venugopal P, Shah R, Hernandez B, Klein M, Alston D, Robin E, Dominquez C, Raza A. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leukemia Res 1996; 20: 891-900.
40. Janowska-Wieczorek A, Belch AR, Jacobs A, Bowen D, Padua RA, Paietta E, Stanley ER. Increased circulating colony-stimulating factor-1 in patients with preleukemia, leukemia, and lymphoid malignancies. Blood 1991; 77: 1796-1803.
41. Tobal K, Pagliuca A, Bhatt B, Bailey N, Layton DM, Mufti GJ. Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 1990; 4: 486-489.
42. Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A, Trout AB, Ledbetter JA, Deeg HJ. A role for tumour necrosis factor-alpha, Fas, and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998; 103: 176-188.
43. Ganser A, Ottmann OG, Seipelt G, Lindemann A, Hess U, Geissler G, Maurer A, Frisch J, Schulz G, Mertelsmann R, Hoelzer D. Effect of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes. Leukemia 1993; 7: 696-701.
44. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, Parcharidou A, Dar S, Venugopal P, Borok R, Gezer S, Showel J, Loew J, Robin E, Rifkin S, Alston D, Hernandez B, Shah R, Kaizer H, Gregory S. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol 1996; 63: 265-278.
45. Peddie CM, Wolf CR, McLellan LI, Collins AR, Bowen DT. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-α concentration. Br J Haematol 1997; 99: 625-631.
46. Nemunaitis J, Rosenfeld C, Getty L, Boegel F, Meyer W, Jennings LW, Zeigler Z, Shadduck R. Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome. Am J Clin Oncol 1995; 18: 189-193.
47. Raza A, Gezer S, Venugopal P, Kaizer H, Hines C, Thomas R, Alvi S, Mundle S, Shetty V, Borok R, Lowe J, Reza S, Robin EL, Rifkin SD, Alston D, Hernandez B, Shah R, Hsu WT, Dar S, Gregory SA. Hematopoietic and cytogenetic responses to novel anti-cytokine therapy in myelodysplastic syndromes (MDS). Proc ASCO 1997; 16: 7a (Abstr.).
48. Hattori K, Hirano T, Miyajima H, Yamakawa N, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K. Differential effects of antiFas ligand and anti-tumor necrosis factor α antibodies on acute graft-versus-host disease pathologies. Blood 1998; 91: 4051-4055.
49. Nisticò A, Young NS. Gamma-interferon gene expression in the bone marrow of patients with aplastic anemia. Ann Intern Med 1994; 120: 463-469.
50. Mundle SD, Venugopal P, Cartlidge JD, Pandav DV, Broday-Robinson L, Gezer S, Robin EL, Rifkin SR, Klein M, Alston DE, Hernandez BM, Rosi D, Alvi S, Shetty VT, Gregory SA, Raza A. Indication of an involvement of interleukin-1β converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood 1996; 88: 2640-2647.
51. Wetzler M, Kurzrock R, Estrov Z, Esley E, Talpaz M. Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia. Leukemia Res 1995; 19; 23-34.
52. Holmberg L, Seidel K, Leisenring W, Torok-Storb B. Cytokine production by long-term marrow cultures established from myelodysplastic patients. Exp Hematol 1994; 22: 741 (Abstr.).
53. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A, Loew J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S, Preisler H. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietir cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268-276.
54. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996; 88: 4275-4287.
55. Bouscary D, De Vos J, Guesnu M, Jondeau K, Viguier F, Melle J, Picard F, Dreyfus F, Fontenay-Roupie M. Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997; 11: 859-845.
56. Parker JE, Mufti GJ. Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes. Br J Haematol 1998; 101: 220-230.
57. Irvine AE, Magill MK, Somerville LE, McMullin MF. Spontaneous intramedullary apoptosis is present in disorders other than myelodysplasia. Exp Hematol 1998; 26: 455-439.
58. Bogdanović AD, Trpinac DP, Janoković GM, Bumbas̄irević VZ̄, Obradović M, C̄olovic MD. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia 1997; 11: 656-659.
59. Gupta P, Niehans GA, LeRoy SC, Gupta K, Morrison VA, Schultz C, Knapp DJ, Kratzke RA. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia 1999; 13: 44-53.
60. Kitagawa M, Yamaguchi S, Takahaski M, Tanizawa T, Hirokawa K, Kamiyama R. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia 1998; 12: 486-492.
61. Davis RE, Greenberg PL. Bcl-2 expression by myeloid precursors in myelodysplastic syndrome: relation to progression. Leukemia Res 1998; 22: 767-777.
62. Mundle S, Mativi BY, Bagai K, Feldman G, Cheema G, Gautam U, Reza S, Cartlidge J, Venugopal P, Shetty V, Gregory SA, Raza A. A possible link of tumor necrosis factor a (TNFa) with down-regulation of Fas-associated phosphatase-1 (fap-1) and activation of Fas-mediated apoptosis in myelodysplasia. J Clin Oncol 1999; 18: 22a (Abstr.).
63. Klimecki W, Heaton K, Gibson BG, List AF. Amifostine suppresses apoptosis in myelodysplastic CD34+ cells and promotes progenitor cell growth via polyamine-like effects. Blood 1997; 90 (Suppl. 1): 520a (Abstr.).
64. List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R, Capizzi R. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 1997: 90: 3364-3369.
65. Bowen DT, Denzlinger C, Brugger W, Culligan D, Gelly K, Adlakha S, Groves M, Hepurn M, Kanz L. Poor response rate to a continuous schedule of amifostine therapy for 'low/intermediate risk' myelodysplastic patients. Br J Haematol 1998; 103: 785-787.
66. Garcia-Bermejo L, Pérez C, Vilaboa N, de Blas E, Aller P. cAMP increasing agents attenuate the generation of apoptosis by etoposide in promonocytic leukemia cells. J Cell Sci 1998, 111: 637-644.
67. Caligo MA, Cipollini G, Petrini M, Valentini P, Bevilacqua G. Down regulation of NM23.H1, NM23.H2 and c-myc genes during differentiation induced by 1,25 dihydroxyvitamin D3. Leukemia Res 1996; 20: 161-167.
68. Calabretta B, Skorski T. Targeting c-myc in leukemia. Anticancer Drug Des 1997; 12: 375-381.
69. Greenberg PL. Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes. Semin Hematol 1996; 33: 163-175.
70. Aul C, Gattermann N, Schneider W. Comparison of in vitro growth characteristics of blast cell progenitors (CFU-L) in patients with myelodysplastic syndromes and acute myeloid leukemia. Blood 1992; 80: 625-633.
71. Sawada K, Sato N, Notoya A, Tarumi T, Hirayama S, Takano H, Koizumi K, Yasukouchi T, Yamaguchi M, Koike T. Proliferation and differentiation of myelodysplastic CD34+ cells: phenotypic subpopulations of marrow CD34+ tells. Blood 1995; 85: 194-202
72. Santini V, Ferrim PR. Differentiation therapy of myelodysplastic syndromes: fact or fiction? Br J Haematol 1998; 102: 1124-1138.
73. Mellibovsky L, Diez A, Pérez-Vila E, Serrano S, Nacher M, Aubía J, Supervía A, Recker RR. Vitamin D treatment in myelodysplastic syndromes. Br J Haematol 1998; 100: 516-520.
74. Howard MR, Bond LR. Calcitriol in myelodysplastic syndromes. Br J Haematol 1999; 106: 569-574.
75. Bowen D, Yancik S, Bennett L, Culligan D, Resser K. Serum stem cell factor concentration in patients with myelodysplastic syndromes. Br J Haematol 1993; 85: 53-66.
76. Zwierzina H, Schöllenberger S, Herold M, Schmalzl F, Besemer J. Endogenous serum levels and surface receptor expression of GM-CSF and IL-3 in patients with myelodysplastic syndromes. Leukemia Res 1992; 16: 1181-1186.
77. Gidáli J, Fehér I, Hollán S. Blast colony forming cell-binding capacity of bone marrow stroma from myelodysplastic patients. Stem Cell 1996; 14: 577-583.
78. Tennant GB, Truran LN, Kell WJ, Burnett AK. Myelodysplastic bone marrow stroma is detective in its ability to sustain normal stem cell growth. Blood 1997; 90 (Suppl. 1): 582a (Abstr.).
79. Greenberg PL, Mackichan ML, Negrin R, Renick M, Ginzton N. Production of granulocyte colony stimulating factor (G-CSF) by normal and myelodysplastic syndrome (MDS) peripheral blood (PB) cells. Blood 1990; 76: (Suppl. 1) 146a (Abstr.).
80. Visani G, Zauli G, Tosi P, Fogli M, Cenacchi A, Finelli C, Gamberi B, Ottaviani E, Manfoi S, Tura S. Impairment of GM-CSF production in myelodysplastic syndromes. Br J Haematol 1993; 84: 227-231.
81. Ganser A, Karthaus M. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Leuk Lymphoma 1997; 26 (Suppl. 1): 13-29.
82. Mencoboni M, Castello G, Lerza R, Haupt E, Ballarine P, Cerruti A, Bogliolo G, Pannacciulli I. Production of tumor necrosis factor and granulocyte colony stimulating factor by bone marrow accessory cells in myelodysplastic patients. Eur J Haematol 1996; 56: 148-152.
83. Cortelezzi A, Cattaneo C, Cristiani S, Sarina B, Pomati M, Silvestris I, Ibatici A, Maiolo AT. Low plasma stem cell factor levels correlate with in vitro leukemic growth in myelodysplastic syndromes. Leukemia Res 1999; 23: 271-275.
84. Merchav S, Nagler A, Fleischer-Kurtz G, Tatarsky I. Regulatory abnormalities in the marrow of patients with myelodysplastic syndromes. Br J Haematol 1989; 73: 158-164.
85. Zwierzina H, Anderson JE, Rollinger-Holzinger I, Torok-Storb B, Nuessler V, Lyman SD. Endogenous FLT-3 ligand serum levels are associated with disease stage in patients with myelodysplastic syndromes. Leukemia 1999; 13: 553-557.
86. Ohyashiki JH, Iwama H, Yahata N, Ando K, Hayashi, Shay JW, Ohyashiki K. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin Cancer Res 1999; 5: 1155-1160.
87. Boultwood J, Fidler C, Kusec R, Rack K, Elliott JW, Atoyebi O, Chapman R, Oscier DG, Wainscoat JS. Telomere length in myelodysplastic syndromes. Am J Hematol 1997; 56: 266-271.
88. Sharma S, Raymond E, Soda H, Sun D, Hilsenbeck SG, Sharma A, Izbicka E, Windle B, Von Hoff DD. Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Ann Oncol 1997; 8: 1063-1074.
89. Kirsch DG, Kastan MB. Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Ontol 1998; 16: 3158-3168.
90. Sugimoto K, Hirano N, Toyoshima H, Chiba S, Mano H, Takaku F, Yazaki Y, Hirai H. Mutations of the p 53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 1993; 81: 3022-3026.
91. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux. p 53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148-3157.
92. Mitani K, Hangaishi A, Imamura N, Miyagawa K, Ogawa S, Kanda V, Yazaki Y, Hirai H. No concomitant occurrence of the N-ras and p 53 gene mutations in myelodysplastic syndromes. Leukemia 1997; 11: 863-865.
93. Adamson DJA, Dawson AA, Bennett B, King DJ, Haites NE. p 53 mutation in the myelodysplastic syndromes. Br J Haematol 1995; 89:61-66.
94. Preudhomme C, Fenaux P. The clinical significance of mutations of the p 53 tumour suppressor gene in haematological malignancies. Br J Haematol 1997; 98: 502-511.
95. Nielsen LL, Maneval DC. p 53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 1998; 5: 52-63.
96. Bishop MK, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL, Ruddon R, Zon G, Spinolo J, Arneson M, Armitage JO, Kessinger A. Phase I trial of an antisense oligonucleotide OL(1) p 53 in hematologic malignancies. J Clin Oncol 1996; 14: 1320-1326.
97. Masuya M, Kita K, Shimizu N, Ohishi K, Kalaya N, Sekine T, Otsuji A, Miwa H, Shirakaw S. Biologic characteristics of acute leukemia after myelodysplastic syndrome. Blood 1993; 81: 3388-3394.
98. INK4B gene in myelodysplastic syndromes. Blood 1997; 90: 1403-1409.
99. INK4B gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998; 91: 2985-2990.
100. Bender CM, Zingg JM, Jones PA. DNA methylation as a target for drug design. Pharm Res 1998; 15: 175-187.
101. Momparler RL, Cote S, Eliopoulos N. Pharmacological approach for optimization of the dose schedule of 5-Aza-2′-deoxycytidine (Decitahine) for the therapy of leukemia. Leukemia 1997; 11: 175-180.
102. Silverman LR, Demakos EP, Peterson B, Odchimar-Reissig R, Nelson D, Kornhlith AB, Stone R, Holland JC, Powell BL, DeCatro C, Ellerton J, Larson RA, Schiffer CA, Holland JF. A randomized controlled trial of subcutaneous azacitidine (AZA C) in patients with the myelodysplastic syndrome (MDS): a study of the Cancer and Leukemia Group B (CALGB). Proc ASCO 1998; 17: 14a (Abstr.).
103. INK4B1. Cancer Res 1996; 56: 722-727.
104. Wijermans PW, Krulder JWM, Huijgens PC, Neve P. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997; 11: 1-5.
105. Lubbert M, Haak HL, Kunzmann R, Danzer-Driessen S, Verhoef G, Mertelsmann R, Wijermans P. Cytogenetic response to low-dose 5-Aza-2′-deoxycytidine (DAC) in poor-risk myelodysplastic syndromes (MDS)-phase II study results. Blood 1997; 90: 582a (Abstr.)
106. Ball SE, Gibson FM, Rizzo S, Tooze JA, March JCW, Gordon-Smith EC. Progressive telomere shortening in aplastic anemia. Blood 1998; 91: 3582-3592.
107. Nakao S, Yamaguchi M, Shiobara S, Yokoi T, Miyawaki T, Taniguichi T, Matsuda T. Interferon-γ gene expression in unstimulated bone marrow mononuclear cells predicts a good response to cyclosporine therapy in aplastic anaemia. Blood 1992; 79: 2532-2535.
108. Hinterberger W, Adolf G, Bettelheim P, Geissier K, Huber C, Irschick E, Kalhs P, Köller U, Lechner K, Meister B, Woloszcszuk W. Lymphokine overproduction in severe aplastic anemia is not related to blood transfusions. Blood 1989; 74: 2713-2717.
109. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. New Engl J Med 1997; 336: 1365-1372.
110. Philpolt NJ, Scopes J, Marsh JC, Gordon-Smith EC, Gibson FM. Increased apoptosis in aplastic anemia bone marrow progenitor cells: possible pathophysiologic significance. Exp Hematol 1995; 23: 1642-1648.
111. Callera F, Falcao RP. Increased apoptotic cells in bone marrow biopsies from patients with aplastic anaemia. Br J Haematol 1997; 98: 18-20.
112. Raghavachar A, Janssen JWG, Schrezenmeier H, Wagner B, Bartram CR, Schulz AS, Hein C, Cowling G, Mubarik A, Testa NG, Dexter TM, Hows JM, Marsh JCW. Clonal hematopoiesis as defined by polymorphic X-linked loci occurs infrequently in aplastic anemia. Blood 1995; 86: 2938-2947.
113. Kojima S, Matsuyama T, Kodera Y. Hematopoietic growth factors released by marrow stromal cells from patients with aplastic anemia. Blood 1992: 79: 2256-2261.